NIPH Clinical Trials Search

Basic Information

Recruitment status
Health condition(s) or Problem(s) studied	psoriasis
Date of first enrollment	05/08/2010
Target sample size
Countries of recruitment
Study type	Interventional
Intervention(s)	investigational material(s) Generic name etc : AIN457 INN of investigational material : Therapeutic category code : 399 Agents affecting metabolism, n.e.c. Dosage and Administration for Investigational material : Subcutaneously Administered

Outcome(s)

Primary Outcome	Safety and tolerability as measured by Adverse Events and clinically significant changes in vital signs and clinical laboratory variables.
Secondary Outcome	Long-term efficacy as assessed by PASI 50, PASI 75 and PASI 90 achievement and an improvement of the IGA during the trial.

Key inclusion & exclusion criteria

Age minimum	>= 18age old
Age maximum	Not applicable
Gender	Both
Include criteria	- Patients who completed the core study ( A Multicenter Trial of Subcutaneously Administered AIN457 in Patients With Moderate to Severe Chronic Plaque-type Psoriasis)
Exclude criteria	-Patients who experience a second consecutive full relapse at visit 13 of the core study ( A Multicenter Trial of Subcutaneously Administered AIN457 in Patients With Moderate to Severe Chronic Plaque-type Psoriasis) Other protocol-defined inclusion/exclusion criteria may apply